Premium
Biologics, an alternative therapeutic approach for oral lichen planus
Author(s) -
Zhang Jing,
Zhou Gang,
Du GeFei,
Xu XueYi,
Zhou HongMei
Publication year - 2011
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2011.01029.x
Subject(s) - oral lichen planus , pathogenesis , medicine , immunology , autoimmune disease , disease , cancer research , pathology
J Oral Pathol Med (2011) 40 : 521–524 Oral lichen planus (OLP) is generally accepted as a chronic and T‐cell‐mediated autoimmune disease, whose immunopathogenesis may involve antigen presentation, T‐cell activation and migration as well as, possibly, tumor necrosis factor‐alpha (TNF‐α)‐induced keratinocytes apoptosis. However, present treatment options for OLP are far from being satisfactory. Recent advances in understanding the pathogenesis of OLP, progress in biologics, and the success of biologic therapies in OLP indicate that biologic agents are facing expanding indications in OLP. In this review, we mainly discuss the role of T cells in the pathogenesis of OLP and several biologic therapies that directly and/or indirectly target T cells to treat OLP.